The Impact of Technological Advancements on Minimal Residual Disease Market Research: Current Trends The global Minimal Residual Disease (MRD) market size was USD 1,095.3 Million in 2021 and is expected to register a revenue CAGR of 16.04% during the forecast period, according to the latest analysis by Emergen Research. Rising R&D activities and increase in research funding from various cancer institutes are major factors projected to support market revenue growth between 2021 and 2030. For instance, Invitae Corporation, based in the U.S., started a research in February 2022 to collect actual data on tailored minimal residual disease diagnostics for distinct tumor types. Inivata also introduced RaDaR assay in April 2020 to identify and track residual disease and relapse in plasma samples of patients with prior cancer diagnoses. In addition, RaDaR assay is based on next-generation sequencing platform InVision liquid biopsy, developed by Inivata, which has built-in control and error checking for highly sensitive and precise variant detection. Moreover, to improve testing and detection outcomes, companies competing in the worldwide MRD testing market are concentrating more on disease-specific and tailored diagnostic kits, which is also expected to drive revenue growth of the market. The report demonstrates the progress and advancement achieved by the global Minimal Residual Disease market, including the historical analysis and progress through forecast years. The report provides valuable insights to the stakeholders, investors, product managers, marketing executives, and other industry professionals. The report provides an accurate estimation by applying SWOT analysis and Porter’s Five Forces analysis. Request a Sample Report with Table of Contents and Figures to click Here: https://www.emergenresearch.com/request-sample/1352 Competitive Terrain: The section on the competitive landscape offers valuable and actionable insights related to the business sphere of the Minimal Residual Disease market, covering extensive profiling of the key market players. The report offers information about market share, product portfolio, pricing analysis, and strategic alliances such as mergers and acquisitions, joint ventures, collaborations, partnerships, product launches and brand promotions, among others. The report also discusses the initiatives taken by the key companies to combat the impact of the COVID-19 pandemic. The leading market contenders listed in the report are: Adaptive Biotechnologies, ARUP Laboratories, Bio-Rad Laboratories, Inc., Cergentis B.V., F. Hoffmann-La Roche Ltd., ICON Plc, Invivoscribe, Inc., Laboratory Corporation of America Holdings, Mission Bio, Natera, Inc., NeoGenomics Laboratories, OPKO Health, Inc., and Sysmex Corporation Click to access the Report Study, Read key highlights of the Report and Look at Projected Trends: https://www.emergenresearch.com/industry-report/minimal-residual-disease-market